-
Political use of misinformation impacts Covid-19 vaccination of children in Brazil
-
Fiocruz invests in malaria vaccines with Japanese support
Fiocruz Amazônia, in partnership with the Tropical Medicine Foundation (FMT), is participating in a pre-clinical trial project for a vaccine against the vivax variety of malaria
Learn more -
COVID-19: Fiocruz and MSD sign an agreement to produce the first oral antiviral drug in Brazil
The Fiocruz Institute of Drug Technology (Farmanguinhos/Fiocruz) signed an agreement of technological cooperation with the American pharmaceutical company MSD (Merck Sharp & Dohme)
Learn more -
Fiocruz receives the WHO's technical lead on COVID-19 and delegations of PAHO and Ministry of Health
Delegations debated lessons learned and challenges to maintain investments that were focused on the pandemic's preparedness for possible new public health emergencies.
Learn more -
Fiocruz participates in the construction of a health surveillance program on the borders
Representatives from Brazil, France, French Guiana, Fiocruz, PAHO and the Pasteur Institute of Guiana participated in the 3rd Transborder Workshop on Health Surveillance
Learn more -
Research evaluates the effectiveness of four vaccines in cases of reinfection by COVID-19
The highest effectiveness was observed with the four vaccines in use in Brazil (Coronavac, AstraZeneca, Janssen, and Pfizer-BioNTech) in the prevention of COVID-19
Learn more -
Open Science: new courses from Fiocruz are incorporated to The Global Health Network
Welcome!
The Oswaldo Cruz Foundation (Fiocruz) is the most prominent Institution of Science and Technology in Health in Latin America, based in Brazil. Its mission is to produce, disseminate and share knowledge and technologies
|
|
|
|
||
|
|
|
|
|
|